



*Quality of Science, Speed of Execution,  
Passion for Improving the lives of Patients*

CORPORATE FACT SHEET | JULY 2010

## SYNTA OVERVIEW

Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a unique chemical compound library, an integrated discovery engine, and a pipeline of small molecule drug candidates with novel chemical structures and distinct mechanisms of action. All drug candidates were invented internally by Synta scientists using our compound library and discovery capabilities.

## COMPANY HIGHLIGHTS

**Strong pipeline of novel internally-developed candidates in cancer and inflammatory disease** including: **STA-9090**, a potent, second-generation, small molecule Hsp90 inhibitor currently in eight cancer trials; **elesclomol**, a first-in-class oxidative stress inducer for cancer; **STA-9584**, a dual-acting vascular disrupting agent; an oral/topical **IL-12/IL-23** inhibitor program for autoimmune and inflammatory diseases; and a **CRACM** ion channel inhibitor program for chronic inflammatory diseases and transplant rejection. All programs are 100% owned by Synta except for the CRACM program.

**Partnership with Roche for developing novel CRACM inhibitors.** Synta leads discovery; Roche leads development and commercialization. Synta receives all research, preclinical and clinical costs reimbursed; royalties on approved products; and up to \$1 billion in potential milestone payments.

**Unique drug discovery engine** that has generated all Synta compounds to date and continues to generate promising, novel, small-molecule drug candidates. Platform based on unique chemical library; high throughput screening and in vivo modeling capabilities; medicinal, computational, analytic, process-development chemistry expertise; in vitro and in vivo toxicology and DMPK experience.

**Strong financial position** with approximately \$58 million in cash at end of Q1 2010. Raised \$26.7 million net in January 2010 through public offering. Substantial majority of partnered program costs are reimbursed, significantly lowering expenses. Cash sufficient to fund company operations into 2012.

**Strong intellectual property position** with portfolio of over 700 issued or pending patents. All Synta compounds currently in clinical trials represent novel chemical structures protected by issued or allowed composition of matter patents and related structure, mechanism, formulation, manufacturing, and administration patents.

## AT-A-GLANCE

As of July 15, 2010  
NASDAQ: SNTA  
Recent price: \$2.90  
52-week range: \$2.24 - \$6.95  
Shares outstanding: 40,484,389  
Market Cap: \$117.4 million  
Analyst Coverage: Barclays,  
Canaccord, Lazard, Roth, RBC

## SENIOR MANAGEMENT

**Safi Bahcall, Ph.D.**  
President, Chief Executive Officer

**Michael Bailey, MBA**  
SVP Business Development and  
Chief Commercial Officer

**Keith Ehrlich, C.P.A.**  
VP, Chief Financial Officer

**Keizo Koya, Ph.D.**  
SVP, Drug Development

**Arthur McMahon**  
VP, Human Resources

**Wendy Rieder, Esq.**  
VP, General Counsel

**Vojo Vukovic, M.D., Ph.D.**  
SVP, Chief Medical Officer

## IR CONTACT

**Rob Kloppenburg**  
VP, Investor Relations and  
Corporate Communications  
(781) 541-7125  
ir@syntapharma.com

Synta Pharmaceuticals Corp.  
45 Hartwell Avenue  
Lexington, MA 02421  
Tel: (781) 274-8200  
Fax: (781) 274-8228

This document may contain forward-looking statements about Synta Pharmaceuticals Corp. including statements relating to the timing and progress of our clinical and preclinical programs and the timing and amounts of milestone payments under our agreement with Roche and the expected amount of our cash to fund company operations into 2012. These forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those risks and uncertainties described under "Risk Factors" in our Form 10-K for the year ended December 31, 2009 as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

